Australian Clinical Study Published in British Journal of Dermatology Presents Further Benefits With Nevisense

Source: PR Newswire, May 2017

The Australian study previously presented at the World Congress of Cancers of the Skin showing that Nevisense can detect malignant melanoma three months earlier in follow-up cases and reduce the need for follow-up by nearly half, has now been published in the British Journal of Dermatology (BJD). The BJD is one the world’s leading journals within dermatology research and this is the second time that they publish an article about Nevisense and the EIS method.

In the study, conducted by Dr Lilian Rocha, Associate Prof. Pascale Guitera, Prof. Scott W. Menzies et. al. at the Melanoma Institute of Australia and Royal Prince Alfred Hospital in Sydney, short term digital dermoscopy imaging (SDDI) was combined with Nevisense’s electrical impedance spectroscopy (EIS). In total, the use of Nevisense showed the potential to reduce the number of cases that needed to undergo SDDI by 47%. This could simplify diagnostics and lead to significant cost savings for health care while shortening many patients’ waiting time for a diagnosis with approximately three months.
read the original full article

Melanoma Google Alerts

Melanoma Google Alerts is a summary of daily articles found in print and on the internet. The articles do not necessarily represent the views of Melbourne Melanoma Project

News Archives

News Categories